Iterum Therapeutics (ITRM) Insider Trading & Ownership $0.69 -0.01 (-0.79%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$0.72 +0.02 (+3.24%) As of 04:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Iterum Therapeutics (NASDAQ:ITRM) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.40%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$113.70KNumber OfInsiders Selling(Last 3 Years)2Amount OfInsider Selling(Last 3 Years)$160.44K Get ITRM Insider Trade Alerts Want to know when executives and insiders are buying or selling Iterum Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ITRM Insider Buying and Selling by Quarter Iterum Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/22/2023Michael W DunneDirectorBuy25,000$1.40$35,000.00 11/22/2023Michael W DunneDirectorBuy20,000$2.03$40,600.00 11/20/2023Corey N FishmanCEOBuy10,000$1.59$15,900.00 12/2/2022Sailaja PuttaguntaInsiderSell3,365$1.32$4,441.80 9/19/2022Brenton Karl AhrensDirectorSell15,000$1.77$26,550.00 9/16/2022Brenton Karl AhrensDirectorSell15,000$1.90$28,500.00 9/14/2022Brenton Karl AhrensDirectorSell15,000$2.10$31,500.00 9/12/2022Brenton Karl AhrensDirectorSell15,000$2.31$34,650.00 9/9/2022Brenton Karl AhrensDirectorSell15,000$2.32$34,800.00 9/7/2022Michael W DunneDirectorBuy10,000$2.22$22,200.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. (Data available from 1/1/2013 forward) ITRM Insider Trading Activity - Frequently Asked Questions Who is on Iterum Therapeutics' Insider Roster? The list of insiders at Iterum Therapeutics includes Brenton Karl Ahrens, Corey N Fishman, Michael W Dunne, and Sailaja Puttagunta. Learn more on insiders at ITRM. What percentage of Iterum Therapeutics stock is owned by insiders? 2.40% of Iterum Therapeutics stock is owned by insiders. Learn more on ITRM's insider holdings. Which Iterum Therapeutics insiders have been buying company stock? The following insiders have purchased ITRM shares in the last 24 months: Corey N Fishman ($15,900.00), and Michael W Dunne ($75,600.00). How much insider buying is happening at Iterum Therapeutics? Insiders have purchased a total of 55,000 ITRM shares in the last 24 months for a total of $91,500.00 bought. Iterum Therapeutics Key ExecutivesMr. Corey N. Fishman (Age 59)President, CEO & Director Compensation: $1.3MMs. Judith M. Matthews (Age 54)Chief Financial Officer Compensation: $747.77kDr. Michael W. Dunne M.D. (Age 64)Strategic Advisor & Director Compensation: $115kDr. Sailaja Puttagunta M.D. (Age 55)Chief Medical Officer Compensation: $946.83kMr. Tom Loughman Ph.D.Senior Vice President of Technical OperationsMs. Louise BarrettSenior Vice President of Legal Affairs & SecretaryDr. Steven I. Aronin M.D.Senior VP & Head of Clinical Development More Insider Trading Tools from MarketBeat Related Companies Fate Therapeutics Insider Trades Seres Therapeutics Insider Trades Immuneering Insider Trades Protalix BioTherapeutics Insider Trades Inhibikase Therapeutics Insider Trades Protara Therapeutics Insider Trades FitLife Brands Insider Trades Anebulo Pharmaceuticals Insider Trades OKYO Pharma Insider Trades Corbus Pharmaceuticals Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:ITRM) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
